EUCTR2004-002712-28-IT进行中（未招募）不适用
Chronic iloprost administration in scleroderma patients effect on disease progression, as assessed by skin fibrosis evaluation. A randomized, controlled, blind-observer, multicenter phase III study.
ITALFARMACO0 个研究点目标入组 69 人开始时间: 2006年2月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)SclerodermaInterstitial Lung DiseaseNCT00883129Michael Roth142
进行中（未招募）
1 期
ew therapy for patients suffering Acute Respiratory Distress SyndromeEUCTR2016-003168-37-DEniversity Tuebingen150
已完成
不适用
SCOT Scleroderma Treatment Alternative Registry (STAR Registry)Scleroderma, SystemicSclerosisNCT00860548National Institute of Allergy and Infectious Diseases (NIAID)19
尚未招募
不适用
Dermoscopy of steroid modified tineaCTRI/2021/02/031323GSL medical college and general hospital
进行中（未招募）
不适用
ow-dose oral imatinib in the treatment of scleroderma pulmonary involvement: a phase II pilot study - Imatinib in sclerodermaMedDRA version: 6.1Level: PTClassification code 10042953Systemic SclerosisEUCTR2007-005322-68-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI